Canadian scientists have developed a new method that can deliver cancer drugs precisely to tumors.

This article is the original translation of the translational medicine network. Please indicate the source: Cathy introduction: Nowadays, colorectal cancer has become a common cancer type. Its incidence rate and mortality rate are at the forefront in the world. The number of new cases in 2018 reached nearly 2 million, and the number of deaths was nearly 900 thousand.in China, the number of colorectal cancer patients also showed a significant upward trend.recently, researchers from Canada have developed a technology that can more accurately deliver anticancer drugs to the tumor site of colorectal cancer.up to now, the main nanoparticle materials used for drug delivery are polymers, and the drug can be released slowly or controlled by diffusion or degradation of the polymer itself.recently, researchers from the University of Alberta, Canada, have modified nanoparticles to deliver anticancer drugs more accurately to colorectal cancer.the study was led by oncologist Frank wuest of the University of Alberta in Canada and published in the journal Molecular pharmaceutics.the title is "synthesis and analysis of 64Cu labeled ge11 modified polymeric mica nanoparticles for EGFR targeted molecular imaging in a colorectic cancer model".however, tracking their biodistribution, stability and clearance in vivo is a challenge.in this study, scientists modified the surface of nanoparticles with epidermal growth factor (EGF), a peptide that binds to EGF receptors on cancer cells.he then labeled the nanoparticles with radioactive tracers and observed their location by positron emission tomography (PET) to test whether the modified nanoparticles were specifically targeted at tumor cells.in vitro fluorescence studies showed that compared with SW620 cells with EGFR negative expression, ge11 micelles significantly enhanced the internalization of EGFR expressing HCT116 colon cancer cells.then they labeled the micelles with radioactive 64Cu for positron emission tomography.the analysis of 64Cu labeled micelles in vivo showed that the blood circulation was prolonged and the liver and gallbladder clearance rate was increased.wuest said: "we found that these EGF modified nanoparticles exhibited higher aggregation in tumor cells while retaining healthy cells."he is also a member of the Northern Alberta Cancer Institute (crina).Frank wuest is also working with crina members Michael Weinfeld and Afsaneh lavasanifar on a larger study aimed at improving the treatment of colorectal cancer by targeting specific components of DNA repair mechanisms.the tested and modified nanoparticles will be loaded with a drug developed by another project team and deployed to colorectal cancer cells.wuest said: "through our imaging technology, we can achieve targeted delivery of nanoparticles to cancer and tumor.now we will integrate these anticancer drugs into the nanoparticle platform."although wuest's team has focused on colorectal cancer in particular, he points out that the general nanoparticle platform used for drug delivery can be used in conjunction with a variety of other anti-cancer drugs.this will help anti-cancer drugs to target cancer cells more precisely, so as to improve drug utilization and reduce side effects.Ref.: [1] Igor Paiva et al. Synthesis and analysis of 64Cu labeled ge11 modified polymeric mica nanoparticles for EGFR targeted molecular imaging in a colonial cancer model, Molecular Pharmaceutics (2020). DOI: 10.1021/ acs.molpharmaceut 9b01043 [2] [3] [4] recommended reading: fighting the epidemic situation, transforming medical network content team series report: [new discovery] obesity delays things! Large retrospective analysis showed that the effect of chemotherapy on obese breast cancer patients was poor! [PNAs] a new breakthrough: blocking a protein can inhibit liver cancer and cholangiocarcinoma [PLoS One] research from the University of Pennsylvania shows that luminous dyes can help doctors eliminate cancer cells [breakthrough] scientists from three countries jointly develop a new "detoxification version" of erythromycin, with greatly reduced side effects! Click to read the original